Clinical Trials in Cairns, Queensland

9 recruiting

Showing 19 of 9 trials

Recruiting
Phase 3

Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Unresectable/Metastatic Melanoma
Canadian Cancer Trials Group614 enrolled30 locationsNCT02821013
Recruiting
Phase 2Phase 3

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

End-stage Kidney DiseaseAtherosclerotic Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring2,310 enrolled468 locationsNCT05485961
Recruiting
Phase 3

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Extensive-stage Small-cell Lung Cancer
BioNTech SE621 enrolled138 locationsNCT06712355
Recruiting

IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma

Melanoma (Skin Cancer)
Peter MacCallum Cancer Centre, Australia80 enrolled6 locationsNCT07138222
Recruiting
Not Applicable

Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

Kidney Failure, ChronicHyperphosphatemia
The University of Queensland3,600 enrolled115 locationsNCT03573089
Recruiting

The National Australian HCV Point-of-Care Testing Program - HCV Antibody Testing Minimal Dataset

Hepatitis C
Kirby Institute40,000 enrolled12 locationsNCT05713136
Recruiting

The National Australian HCV Point-of-Care Testing Program

Hepatitis C
Kirby Institute40,000 enrolled56 locationsNCT05042544
Recruiting

The National Australian HCV Point-of-Care Testing Program - Minimal Dataset

Hepatitis C
Kirby Institute40,000 enrolled11 locationsNCT05248555
Recruiting
Not Applicable

ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings

Hepatitis C
Kirby Institute6,000 enrolled29 locationsNCT03685045